{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:09:35Z","timestamp":1793740175460,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"J P Moulton Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3458-3","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T10:03:42Z","timestamp":1500631422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Danielle","family":"Crawley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Challacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Santa Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidelma","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gincy","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"issue":"4","key":"3458_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1078-1439(01)00126-0","volume":"6","author":"AV D'Amico","year":"2001","unstructured":"D'Amico AV. Combined modality staging for clinically localized adenocarcinoma of the prostate as the basis for patient selection for randomized trials of neoadjuvant chemotherapy. Urol Oncol. 2001;6(4):171\u20132.","journal-title":"Urol Oncol"},{"issue":"10","key":"3458_CR2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2011.128","volume":"8","author":"JW Denham","year":"2011","unstructured":"Denham JW. Targeted therapies: an important piece of the localized prostate cancer puzzle? Nat Rev Clin Oncol. 2011;8(10):573\u20134.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3458_CR3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.juro.2011.04.087","volume":"186","author":"PR Womble","year":"2011","unstructured":"Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol. 2011;186(3):882\u20137.","journal-title":"J Urol"},{"issue":"3","key":"3458_CR4","doi-asserted-by":"crossref","first-page":"s843","DOI":"10.1093\/ajcn\/86.3.843S","volume":"86","author":"AW Hsing","year":"2007","unstructured":"Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843\u201357.","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"3458_CR5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/cncr.22461","volume":"109","author":"JL Beebe-Dimmer","year":"2007","unstructured":"Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109(5):875\u201381.","journal-title":"Cancer"},{"issue":"1","key":"3458_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08037050310025735","volume":"13","author":"J Hammarsten","year":"2004","unstructured":"Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13(1):47\u201355.","journal-title":"Blood Press"},{"issue":"10","key":"3458_CR7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1055-9965.1646.13.10","volume":"13","author":"JA Laukkanen","year":"2004","unstructured":"Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2004;13(10):1646\u201350.","journal-title":"Cancer Epidemiol Biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"11","key":"3458_CR8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/aje\/kwj320","volume":"164","author":"AJ Tande","year":"2006","unstructured":"Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164(11):1094\u2013102.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"3458_CR9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/1055-9965.EPI-06-0777","volume":"16","author":"P Tuohimaa","year":"2007","unstructured":"Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16(2):302\u20137.","journal-title":"Cancer Epidemiol biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"3","key":"3458_CR10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1940-6207.CAPR-09-0188","volume":"3","author":"ML Neuhouser","year":"2010","unstructured":"Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res. 2010;3(3):279\u201389.","journal-title":"Cancer Prev Res"},{"issue":"4","key":"3458_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdq443","volume":"22","author":"J Flanagan","year":"2011","unstructured":"Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol Official J Eur Soc Med Oncol \/ ESMO. 2011;22(4):801\u20137.","journal-title":"Ann Oncol Official J Eur Soc Med Oncol \/ ESMO"},{"issue":"12","key":"3458_CR12","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063\u20139.","journal-title":"Diabetes"},{"issue":"1","key":"3458_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12272-011-0112-5","volume":"34","author":"HY Sin","year":"2011","unstructured":"Sin HY, Kim JY, Jung KH. Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin. Arch Pharm Res. 2011;34(1):99\u2013107.","journal-title":"Arch Pharm Res"},{"key":"3458_CR14","unstructured":"Ltd MP: Summary of Product Characteristics Metformin 500mg Tablets."},{"issue":"9","key":"3458_CR15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s10552-009-9407-y","volume":"20","author":"JL Wright","year":"2009","unstructured":"Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control : CCC. 2009;20(9):1617\u201322.","journal-title":"Cancer Causes & Control : CCC"},{"issue":"15","key":"3458_CR16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djt170","volume":"105","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Association between Metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013;105(15):1123\u201331.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"3458_CR17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","volume":"7","author":"S Gandini","year":"2014","unstructured":"Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res. 2014;7(9):867\u201385.","journal-title":"Cancer Prev Res"},{"issue":"25","key":"3458_CR18","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2013.50.7715","volume":"31","author":"KL Penney","year":"2013","unstructured":"Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol Official J Am Soc Clin Oncol. 2013;31(25):3054\u20135.","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"issue":"11","key":"3458_CR19","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1055-9965.EPI-13-0349","volume":"22","author":"K Zu","year":"2013","unstructured":"Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, et al. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2013;22(11):1984\u201393.","journal-title":"Cancer Epidemiol Biomark Prev Publication Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"4","key":"3458_CR20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1158\/1535-7163.MCT-08-0631","volume":"8","author":"HU Park","year":"2009","unstructured":"Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009;8(4):733\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3458_CR21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/pcan.2014.20","volume":"17","author":"AM Joshua","year":"2014","unstructured":"Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, et al. A pilot \u2018window of opportunity\u2019 neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(3):252\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"3458_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.2809","volume":"223","author":"R Flavin","year":"2011","unstructured":"Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011;223(2):283\u201394.","journal-title":"J Pathol"},{"key":"3458_CR23","first-page":"Cd005552","volume":"1","author":"M Costello","year":"2007","unstructured":"Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. The Cochrane Database Syst Rev. 2007;1:Cd005552.","journal-title":"The Cochrane Database Syst Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T08:14:38Z","timestamp":1659255278000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3458-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3458-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]},"article-number":"494"}}